Mylan's Next Up For A Shot At Neulasta Biosimilar After Coherus CRL

FDA issued a complete response letter to Coherus' application for a biosimilar version of Amgen's Neulasta (pegfilgrastim), giving Amgen a reprieve, though Mylan has an application pending at the US agency.